Key result
Low-dose dipyridamole (10 mg) safely prolonged the electrophysiological effects of the adenosine test without provoking additional pulmonary vein reconnection.
Why the study?
Does low-dose intravenous dipyridamole improve the efficacy of the adenosine test for detecting and eliminating dormant conduction after pulmonary vein isolation in patients with paroxysmal atrial fibrillation?
Observational (n=18)
Does low-dose intravenous dipyridamole improve the efficacy of the adenosine test for detecting and eliminating dormant conduction after pulmonary vein isolation in patients with paroxysmal atrial fibrillation?
Low-dose dipyridamole safely prolongs the electrophysiological effects of adenosine testing during pulmonary vein isolation, facilitating the sustained visualization and targeted ablation of dormant conduction gaps.
May enhance adenosine testing for dormant conduction in PVI; leaves open randomized confirmation of clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (2013) conducted an observational in Paroxysmal atrial fibrillation (n=18). Low-dose intravenous dipyridamole vs. Adenosine alone was evaluated on Provocation of additional pulmonary vein reconnection. Low-dose dipyridamole (10 mg) safely prolonged the electrophysiological effects of the adenosine test without provoking additional pulmonary vein reconnection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: